How a New Class of Non-Hormonal Drugs is Transforming Menopause Treatment

For decades, the medical approach to the most disruptive symptoms of menopause has been a binary choice: take hormone replacement therapy (HRT) or endure the discomfort. For the estimated 70% of women who experience vasomotor symptoms—the clinical term for hot flashes and night sweats—this lack of options has been a source of profound frustration.[1]

The stakes are particularly high for women who cannot take HRT due to a history of estrogen-dependent cancers, blood clots, or cardiovascular disease. Without effective pharmacological interventions, many have been forced to navigate sudden, overwhelming waves of heat that disrupt sleep, impair concentration, and diminish workplace productivity.[1][2][7]

Now, a paradigm shift is underway in women's health. A new class of non-hormonal medications, led by the drug fezolinetant (marketed as Veozah or Veoza), is transforming the standard of care. Following its initial approval by the U.S. Food and Drug Administration (FDA) in 2023, the drug has rapidly gained global traction.[3][5][6][8]

In a watershed moment for access, the UK's National Institute for Health and Care Excellence (NICE) issued final draft guidance in March 2026 recommending fezolinetant for use on the National Health Service (NHS). The decision is expected to benefit approximately 500,000 women in England and Wales who are unsuitable for or prefer not to take HRT.[1][2][3][7]

To understand why fezolinetant represents such a breakthrough, it is necessary to look at the brain's temperature control center: the hypothalamus. During the reproductive years, estrogen acts as a stabilizing force on a specific group of neurons in the hypothalamus known as KNDy neurons.[5][9]

As estrogen levels plummet during menopause, these KNDy neurons become hyperactive. They release a chemical messenger called neurokinin B, which binds to neurokinin-3 (NK3) receptors. This binding falsely signals to the brain that the body is overheating, triggering the rapid dilation of blood vessels and the intense sweating characteristic of a hot flash.[2][5][9]

Fezolinetant works by directly intervening in this neural pathway. As an NK3 receptor antagonist, the once-daily 45-milligram tablet blocks neurokinin B from binding to its receptors. By effectively muting the false overheating signal, the medication restores balance to the brain's thermostat without introducing systemic hormones into the body.[1][3][7]

The clinical evidence supporting this mechanism is robust. In the pivotal SKYLIGHT 1 and SKYLIGHT 2 phase III trials, researchers evaluated thousands of postmenopausal women experiencing moderate-to-severe hot flashes. The data demonstrated a statistically significant reduction in both the frequency and severity of vasomotor symptoms compared to a placebo, with improvements noted as early as the first week of treatment.[2][6][9]

Beyond simply reducing the number of hot flashes, the trials highlighted cascading benefits for overall well-being. Participants reported substantial improvements in sleep quality and a reduction in the fatigue that often accompanies chronic night sweats.[6][9]

As the drug has moved from clinical trials into widespread real-world use, long-term safety data has continued to accumulate. At the Endocrine Society (ENDO) Annual Meeting in June 2026, researchers presented a pooled analysis of over 3,100 women followed for up to 52 weeks.[4]

The ENDO 2026 data specifically addressed concerns about the drug's central nervous system profile. Because fezolinetant acts directly on the brain, clinicians wanted to ensure it did not cause cognitive or mood-related side effects. The analysis found no signal for depression, memory impairment, next-day somnolence, or suicidal ideation, providing critical reassurance for patients and prescribers.[4]

The success of fezolinetant has also paved the way for related compounds. In late 2025, the FDA approved elinzanetant (brand name Lynkuet), a dual antagonist that blocks both NK1 and NK3 receptors. The emergence of multiple drugs in this class indicates that neurokinin modulation is becoming a foundational pillar of menopause care.[5][9]

However, the rollout of these medications is not without caveats. While generally well-tolerated, fezolinetant has been associated with rare but serious liver injury. In 2024, the FDA added a boxed warning to the drug's label, and the 2026 NICE guidance mandates liver function testing before initiating treatment and periodically thereafter.[2][5]

Additionally, while the drug offers immense promise for breast cancer survivors—who frequently suffer from severe hot flashes induced by anti-estrogen therapies—regulatory bodies remain cautious. NICE noted that patients with a history of estrogen-dependent cancers should undergo an individual risk assessment before prescription, as specific clinical trial data for this cohort is still maturing.[2][3][9]

Ongoing phase III trials are currently evaluating both fezolinetant and elinzanetant specifically in breast cancer populations. Early reports suggest significant efficacy, and oncologists are hopeful that these non-hormonal options will soon become a standard part of survivorship care.[5][9]

In Japan, Astellas Pharma recently announced positive topline results from the STARLIGHT 2 phase III study, demonstrating the drug's efficacy across diverse genetic populations and paving the way for regulatory filing in the region. The global expansion underscores the universal need for better menopause management.[8]

For decades, the medical establishment often dismissed or minimized the impact of menopausal symptoms. The development and subsequent public health endorsement of targeted, non-hormonal therapies represent a profound shift in how the healthcare system values women's quality of life.[1][7]

By addressing the root neurological cause of vasomotor symptoms, neurokinin antagonists are offering millions of women a chance to reclaim their sleep, their focus, and their comfort. As research continues and access expands, the era of simply enduring menopause may finally be coming to an end.[1][4][7][9]